Headway in Hepatology: Resmetirom’s Historic FDA Approval, What’s Next in MASH
Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.
Related Articles
Warren Buffett buys stakes in three companies after hoarding cash
Warren Buffett has bought stakes in three companies, after hoarding cash for most of 2024.
First autonomous electric loaders in North America get to work
Swedish multinational Sandvik says it’s successfully deployed a pair of fully autonomous Toro LH518iB battery-electric underground loaders.
STAT stories you might have missed in 2024
From AI to patents to H5N1 bird flu to GLP-1s and more, STAT reporters brought analysis and insight to stories on health and the life…
Verity – Quantum Teleportation Achieved Over Internet for First Time
US researchers have teleported a quantum state of light over 30 km (18 miles) of fiber optic cable, a feat deemed impossible earlier. The breakthrough…
Discovering the Clever Way that Flaviviruses Boost Their Own Replication
A Cleveland Clinic-led research team has identified a key protein-modifying mechanism that the Zika virus and other mosquito-transmitted flaviviruses use to hijack infected host cells…
Warren Upton, Oldest Living Survivor of the Pearl Harbor Attack, Dies at 105
Warren Upton, the oldest living survivor of the 1941 attack on Pearl Harbor, and the last living survivor of the USS Utah, has died at…
The US proposes rules to make healthcare data more secure
The HIPAA Security Rule is due for an overhaul.
Healthier Cities Will Require a Strong Dose of Nature
If we can’t get to the forest, the forest must come to us, in the form of cities designed around green spaces.
Top 10 Healthcare Industry Predictions For 2025
Sachin H. Jain’s annual healthcare industry predictions covers a wide range of topics including private equity, the incoming Trump Administration, and executive turnover.
Doctors Say AI Is Introducing Slop Into Patient Care
Early testing demonstrates results that could be disastrous for patients.
